S&P Futures
4,067.50 -17.25 (-0.42%) Dow Futures
32,477.00 -104.00 (-0.32%) Nasdaq Futures
12,487.25 -73.00 (-0.58%) Russell 2000 Futures
1,827.40 -9.80 (-0.53%) Crude Oil
113.97 +1.57 (+1.40%) Gold
1,813.10 -5.80 (-0.32%)
Aridis Pharmaceuticals, Inc. (ARDS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0600 |
| Open | 1.1000 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.1000 - 1.2900 |
| 52 Week Range | 0.8800 - 7.7200 |
| Volume | |
| Avg. Volume | 125,958 |
| Market Cap | 17.567M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.9530 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Zacks
Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2022.
- PR Newswire
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended December 31, 2021.
